Rivipansel subcutaneousAlternative Names: PF-06460031/PF-06744547; PF-06460031/rHuPH20; Rivipansel/PF-06744547; Rivipansel/rHuPH20
Latest Information Update: 10 Nov 2016
At a glance
- Originator GlycoMimetics
- Developer Pfizer
- Class Anti-inflammatories; Antianaemics; Antineoplastics; Glycolipids; Naphthalenesulfonates; Pyrimidines; Small molecules
- Mechanism of Action E-selectin inhibitors; L-selectin inhibitors; P selectin inhibitors; PCSK9 protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Sickle cell anaemia